T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2024
0mins
Source: Newsfilter
Milestone Achievement: T2 Biosystems has surpassed the shipment of 250,000 sepsis tests, demonstrating increased adoption of its rapid diagnostic technology that allows for faster detection and treatment of bloodstream infections compared to traditional blood culture methods.
Clinical Benefits: A meta-analysis shows that T2 Biosystems' tests significantly reduce time to detection and targeted therapy, leading to shorter hospital stays and improved patient outcomes, with results available in just 3-5 hours directly from whole blood.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
